Background and aims The purpose of this study is to use in silico molecular docking and in vivo study to identify the potential of Bryophyllum pinnatum as B cell depleting and immune suppression agent in SLE.
Methods In silico was done by docking 32 phytochemical compounds well known immunosuppresive herbs into three B cell activating receptors: B cell activating factor receptors (BAFF-R), trans- membrane activator and calcium modulator and cyclophilin ligand interactor (TACI), and B-cell maturation antigen (BCMA). In vivo study was done in pristane induced mice model treated with different doses of Bryophyllum pinnatum extract (B1 :10.5 mg/kgBW/day, B2 :21 mg/kgBW/day, and B3 :42 mg/kgBW/day). Extracts were given everyday per orally from 3rd to 4th months after pristane injection. spleen mature B cell (CD19+ CD22+) , Th1,Th2 and Th17 percentages were assessed using flow cytometry assay and serum anti-dsDNA level using ELISA.
Results It was revealed that one compound from Bryophyllum pinnatum had the strongest binding affinity to BAFF-R (−6.3 kcal/mol), to TACI (four compounds,−6.4 kcal/mol) and to BCMA (−7 kcal/mol). In vivo study revealed that Bryophyllum pinnatum treatment significantly lower the percentages of CD19+ CD22+ cell and anti-dsDNA levels in dose dependent manner which significantly lower compared to control (p=0.002 and p=0.036 respectively). Bryophyllum pinnatum treatment lowered also Th1, Th2, and Th17 percentages dose dependently compared to control.
Conclusions Bryophyllum pinnatum is a potential natural product which may be used for B cell depleting agent in SLE treatment by suppressing Th1, Th2 and Th17 percentages.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.